{
  "docId": "019de074-ead2-732b-8415-93449fe93e32",
  "docSlug": "9cc66a7a8f583a45c6978147aa12db97",
  "documentTitle": "Freeman Capital Management | Activist Presentation Deck | 95 slides",
  "authorId": "freeman-capital-management",
  "authorName": "Freeman Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 68,
  "pageCount": 95,
  "prevPage": 67,
  "nextPage": 69,
  "slideType": "timeline",
  "function": "plan_implementation",
  "density": "sparse",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ead2-732b-8415-93449fe93e32/68",
  "deckHref": "/decks/019de074-ead2-732b-8415-93449fe93e32",
  "deckJsonHref": "/decks/019de074-ead2-732b-8415-93449fe93e32.json",
  "deckAnchorHref": "/decks/019de074-ead2-732b-8415-93449fe93e32#slide-68",
  "components": [
    {
      "bbox": {
        "h": 0.117,
        "w": 0.609,
        "x": 0.201,
        "y": 0.361
      },
      "kind": "list",
      "text": "June 20 2023: Meet relevant personnel for MM-402 and obtain the requisite data for the proposed Phase I study of MM-402.",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1add630-cc4c-4b67-b1c9-512d0fdd0119",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.117,
        "w": 0.609,
        "x": 0.201,
        "y": 0.544
      },
      "kind": "list",
      "text": "July 2023: Have meetings with management, clinical personnel, and outside consultants to enhance board's understanding of the MM-402 program.",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3ff2e95-cda7-4ab0-b481-104807bfdba7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.089,
        "w": 0.609,
        "x": 0.201,
        "y": 0.727
      },
      "kind": "list",
      "text": "Aug 1 2023: Determine whether to proceed with the MM-402 program as a core drug.",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec290b12-d201-472c-8523-f2e86085d3a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.089,
        "w": 0.609,
        "x": 0.201,
        "y": 0.208
      },
      "kind": "paragraph",
      "text": "MM-402 is a type of MDMA with supposedly less side-effects. Currently, MindMed is pursuing MM-402 for Autism Spectrum Disorder.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fccc8c44-2b83-447c-9349-cd812dde771f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.133,
        "w": 0.245,
        "x": 0.047,
        "y": 0.056
      },
      "kind": "title",
      "text": "MM-402",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "273929e0-eac9-4e20-a019-ea2f8bb170ef",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "1efabb69-d07b-40c8-ab9f-dab94aed70ca",
      "evidence": "Chronological list of tasks with dates.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 95,
      "from": 61,
      "beatId": "383f2f65-7b68-449f-b311-9bc0591c8aab",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Freeman Capital Management's plan to restore value in Mind Medicine, including bringing MM-120 to market quickly and safely, and aligning G&A and headcount.",
      "position": 2,
      "confidence": 0.9,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 70,
      "from": 62,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "86491bd2-85cc-4539-897c-03a8ac16c31c",
      "evidence": "The document presents Freeman Capital Management's plan to bring MM-120 to market quickly and safely, and to align G&A and headcount.",
      "position": 1,
      "objective": "What are the quick wins and big bets that Freeman Capital Management can make to restore value in Mind Medicine?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}